<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02334787</url>
  </required_header>
  <id_info>
    <org_study_id>271-14-001</org_study_id>
    <nct_id>NCT02334787</nct_id>
  </id_info>
  <brief_title>A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects</brief_title>
  <official_title>A Single-center, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Assess the Safety and Pharmacokinetics of OPA-15406 Ointment in Healthy Adult Male Subjects (Phase 1 Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety (especially skin findings) and pharmacokinetics by applying 0.3%, 1%, or
      3% formulation of 5g OPA-15406 ointment to a 1000 cm2 area as a single-dose and as a
      multiple-dose twice daily for 2 weeks in Japanese healthy adult male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of OPA-15406 in a Single Administration Period</measure>
    <time_frame>Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hr</time_frame>
    <description>We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the Cmax of OPA-15406.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of OPA-15406 in the Multiple Administration Period</measure>
    <time_frame>Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14</time_frame>
    <description>We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC12h of OPA-15406 in a Single Administration Period</measure>
    <time_frame>Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs</time_frame>
    <description>We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the AUC12h x of OPA-15406.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC12h of OPA-15406 in the Multiple Administration Period</measure>
    <time_frame>Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14</time_frame>
    <description>We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>0.3% OPA-15406 in a single administration period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% OPA-15406 in a single administration period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3% OPA-15406 in a single administration period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in a single administration period</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% OPA-15406 in the multiple administration period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% OPA-15406 in the multiple administration period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3% OPA-15406 in the multiple administration period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in the multiple administration period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% OPA-15406 Ointment</intervention_name>
    <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
    <arm_group_label>0.3% OPA-15406 in a single administration period</arm_group_label>
    <arm_group_label>0.3% OPA-15406 in the multiple administration period</arm_group_label>
    <other_name>OPA-15406 Ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% OPA-15406 Ointment</intervention_name>
    <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose</description>
    <arm_group_label>1% OPA-15406 in a single administration period</arm_group_label>
    <arm_group_label>1% OPA-15406 in the multiple administration period</arm_group_label>
    <other_name>OPA-15406 Ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% OPA-15406 Ointment</intervention_name>
    <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
    <arm_group_label>3% OPA-15406 in a single administration period</arm_group_label>
    <arm_group_label>3% OPA-15406 in the multiple administration period</arm_group_label>
    <other_name>OPA-15406 Ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ointment</intervention_name>
    <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
    <arm_group_label>Placebo in a single administration period</arm_group_label>
    <arm_group_label>Placebo in the multiple administration period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI = Body weight (kg) / [Height (m)]2: at least 18.5 and less than 25.0

          -  Judged by the investigator or subinvestigator to be healthy based on test results at
             screening and prior to administration on Day 1 of the treatment period

        Exclusion Criteria:

          -  Findings (sunburn, abrasions, tattoos, etc) on the back that affect the evaluation of
             the safety of the skin

          -  Judged by the investigator or subinvestigator as inappropriate to participate in this
             trial for any other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Ono, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2015</study_first_posted>
  <results_first_submitted>June 7, 2016</results_first_submitted>
  <results_first_submitted_qc>August 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2016</results_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.3% OPA-15406 Ointment</title>
          <description>In a single administration period and the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment.</description>
        </group>
        <group group_id="P2">
          <title>1% OPA-15406 Ointment</title>
          <description>In a single administration period and the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment.</description>
        </group>
        <group group_id="P3">
          <title>3% OPA-15406 Ointment</title>
          <description>In a single administration period and the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>In a single administration period and the multiple administration period, same subjects were treated with assigned placebo ointment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.3% OPA-15406 Ointment</title>
          <description>In a single administration period and the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment.</description>
        </group>
        <group group_id="B2">
          <title>1% OPA-15406 Ointment</title>
          <description>In a single administration period and the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment.</description>
        </group>
        <group group_id="B3">
          <title>3% OPA-15406 Ointment</title>
          <description>In a single administration period and the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>In a single administration period and the multiple administration period, same subjects were treated with assigned placebo ointment.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="7.2"/>
                    <measurement group_id="B2" value="28.3" spread="7.6"/>
                    <measurement group_id="B3" value="30.5" spread="6.7"/>
                    <measurement group_id="B4" value="29.5" spread="6.3"/>
                    <measurement group_id="B5" value="30.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of OPA-15406 in a Single Administration Period</title>
        <description>We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the Cmax of OPA-15406.</description>
        <time_frame>Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.3% OPA-15406 Ointment in a Single Administration Period</title>
            <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3％OPA-15406 ointment assessed until 48 hours postdose.</description>
          </group>
          <group group_id="O2">
            <title>1% OPA-15406 Ointment in a Single Administration Period</title>
            <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.</description>
          </group>
          <group group_id="O3">
            <title>3% OPA-15406 Ointment in a Single Administration Period</title>
            <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of OPA-15406 in a Single Administration Period</title>
          <description>We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the Cmax of OPA-15406.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.508" spread="0.304"/>
                    <measurement group_id="O2" value="0.838" spread="0.531"/>
                    <measurement group_id="O3" value="1.61" spread="0.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of OPA-15406 in the Multiple Administration Period</title>
        <description>We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.</description>
        <time_frame>Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.3 % OPA-15406 Ointment in the Multiple Administration Period</title>
            <description>In the multiple administration period, same subjects were treated with assigned 0.3％OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
          </group>
          <group group_id="O2">
            <title>1 % OPA-15406 Ointment in the Multiple Administration Period</title>
            <description>In the multiple administration period, same subjects were treated with assigned 1％OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
          </group>
          <group group_id="O3">
            <title>3% OPA-15406 Ointment in the Multiple Administration Period</title>
            <description>In the multiple administration period, same subjects were treated with assigned 3％OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of OPA-15406 in the Multiple Administration Period</title>
          <description>We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.506" spread="0.348"/>
                    <measurement group_id="O2" value="0.795" spread="0.208"/>
                    <measurement group_id="O3" value="1.65" spread="0.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC12h of OPA-15406 in a Single Administration Period</title>
        <description>We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the AUC12h x of OPA-15406.</description>
        <time_frame>Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.3% OPA-15406 Ointment in a Single Administration Period</title>
            <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3％OPA-15406 ointment assessed until 48 hours postdose.</description>
          </group>
          <group group_id="O2">
            <title>1% OPA-15406 Ointment in a Single Administration Period</title>
            <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.</description>
          </group>
          <group group_id="O3">
            <title>3% OPA-15406 Ointment in a Single Administration Period</title>
            <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC12h of OPA-15406 in a Single Administration Period</title>
          <description>We measure the plasma concentration of OPA-15406 at Day 1 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as a single dose. We assess the AUC12h x of OPA-15406.</description>
          <units>ng･h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.74" spread="2.32"/>
                    <measurement group_id="O2" value="6.42" spread="4.86"/>
                    <measurement group_id="O3" value="11.2" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC12h of OPA-15406 in the Multiple Administration Period</title>
        <description>We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.</description>
        <time_frame>Baseline, 2 ,3, 4, 8, 10, 12, 16, 24 and 48 hrs at Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.3 % OPA-15406 Ointment in the Multiple Administration Period</title>
            <description>In the multiple administration period, same subjects were treated with assigned 0.3％OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
          </group>
          <group group_id="O2">
            <title>1 % OPA-15406 Ointment in the Multiple Administration Period</title>
            <description>In the multiple administration period, same subjects were treated with assigned 1％OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
          </group>
          <group group_id="O3">
            <title>3% OPA-15406 Ointment in the Multiple Administration Period</title>
            <description>In the multiple administration period, same subjects were treated with assigned 3％OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC12h of OPA-15406 in the Multiple Administration Period</title>
          <description>We measure the plasma concentration of OPA-15406 from Day 1 to Day 14 by applying 0.3%, 1%, or 3% formulation of OPA-15406 ointment as multiple doses twice daily for 2 weeks. We assess the AUC12h x of OPA-15406.</description>
          <units>ng･h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="3.07"/>
                    <measurement group_id="O2" value="7.84" spread="1.78"/>
                    <measurement group_id="O3" value="16.6" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>A single administration: From date of informed consent to 48 hours post dose The multiple administration: From date of assigned IMP twice daily to 16 days post dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.3 % OPA-15406 Ointment in a Single Administration Period</title>
          <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment</description>
        </group>
        <group group_id="E2">
          <title>1% OPA-15406 Ointment in a Single Administaration Period</title>
          <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single and administration period, same subjects were treated with assigned 1% OPA-15406 ointment.</description>
        </group>
        <group group_id="E3">
          <title>3% OPA-15406 Ointment in a Single Administaration Period</title>
          <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, same subjects were treated with assigned 3% OPA-15406 ointment.</description>
        </group>
        <group group_id="E4">
          <title>Placebo in a Single Adminstaration Period</title>
          <description>32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, same subjects were treated with assigned placebo ointment.</description>
        </group>
        <group group_id="E5">
          <title>0.3 % OPA-15406 Ointment in the Multiple Administration Period</title>
          <description>In the multiple administration period, same subjects were treated with assigned 0.3 % OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
        </group>
        <group group_id="E6">
          <title>1 % OPA-15406 Ointment in the Multiple Administration Period</title>
          <description>In the multiple administration period, same subjects were treated with assigned 1 % OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
        </group>
        <group group_id="E7">
          <title>3 % OPA-15406 Ointment in the Multiple Administration Period</title>
          <description>In the multiple administration period, same subjects were treated with assigned 3 % OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
        </group>
        <group group_id="E8">
          <title>Placebo Ointment in the Multiple Administration Period</title>
          <description>In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director, Department of Clinical Management</name_or_title>
      <organization>Otsuka Pharmaceutical Co., LTD.</organization>
      <phone>+81-3-6361-7366</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

